research reports and media, page-4261

Given our optimal dose/minimal effective dose is yet to be authorised.

Given the drug is yet to be classified as a “pain and function” or “Dmoad” drug

Given ambiguity around phase 3 trial metrics

Given TGA may or may not authorise our early application

Given cautious global bio pharma market environment

Given our supplier may also hold some decision making power on partnerships

Given our dire financial situation

……. maybe, just maybe our “deal” potential is held up until some of these dominos fall one way or another.

I’m not for a second saying I’m right here, or that others are wrong. I think some of the slides from last Fridays slide deck are encouraging, though.